Donnette Staas

Donnette Staas has extensive work experience in the pharmaceutical industry. Donnette is currently serving as the Vice President, Regulatory Strategy at Jazz Pharmaceuticals since June 2023. Before that, they held various roles at Merck, including Associate Vice President in the Oncology and Vaccines departments, Executive Director of Global Regulatory Affairs, and Director positions in the Global Regulatory Affairs and Clinical Safety divisions. Prior to joining Merck, Donnette worked as a Senior Research Fellow and Research Fellow. Donnette started their career as a Sr. Research Chemist.

Donnette Staas has a strong educational background in the field of Chemistry. Donnette first attended Columbia University from 1988 to 1992, where they earned an A.B. degree in Chemistry. Donnette then pursued further education at Harvard University from 1992 to 1998, where they received both an A.M. and a Ph.D. in Chemistry.

In 2009, Donnette Staas enrolled at Temple University, where they obtained a Master's degree (MS) in Quality Assurance/Regulatory Affairs in 2011. This indicates their interest in quality control and regulatory compliance within the field.

Aside from their formal education, Donnette Staas also pursued additional certifications to enhance their knowledge and skills. In January 2021, they completed the Black Executive Leadership Program offered by McKinsey & Company. In August 2020, they obtained a certification called "Virus101x: Viruses & How to Beat Them: Cells, Immunity, Vaccines" from IsraeilX (edX). Additionally, in May 2020, they completed the "Vital Signs: Understanding What the Body Is Telling Us" certification from Coursera.

Based on the information provided, Donnette Staas has a strong foundation in Chemistry, with a focus on quality assurance and regulatory affairs. Donnette has also demonstrated a commitment to continuing education through their pursuit of additional certifications.